Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.31 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.30 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2300241 | 0.90 | KDM4E (0.41) | KDM4EPOLBALDH1A1TSHRTDP1 | |
| SCHEMBL2297096 | 0.81 | ATM (0.37) | ALDH1A1TSHRTDP1 | |
| SCHEMBL2299229 | 0.72 | KDM4E (0.31) | KDM4E | |
| SCHEMBL21000316 | 0.72 | GLB1 (0.42) | ALDH1A1TSHRCYP2D6CYP2C19 | |
| SCHEMBL2294529 | 0.72 | GLB1 (0.33) | ALDH1A1CYP2D6CYP2C19 | |
| SCHEMBL2296528 | 0.70 | SIGMAR1 (0.33) | — | |
| SCHEMBL2295851 | 0.70 | CYP2C9 (0.38) | POLBALDH1A1CYP2C19 | |
| SCHEMBL2300211 | 0.70 | ALDH1A1 (0.32) | ALDH1A1 | |
| SCHEMBL2300366 | 0.69 | — | — | |
| SCHEMBL2300257 | 0.69 | DRD4 (0.53) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999006-B2 | Anticancer agents; mitogen-activated protein kinases (MEK) | EXELIXIS, INC. (US) | 2011-08-16 | — | — | US | claimed |